Interestingly recent studies in a murine GBM model utilizing an alternative mTOR inhibitor, RES529, which has been shown to cross the blood-brain barrier, in combination with bevacizumab had reduced tumor progression and increased overall survival [70]. This evidence concerns the gene MTOR and neoplasm.